Company Profile
KalVista Pharmaceuticals, Inc. Stock Price, News & Analysis
Company overview
Business overview
KalVista Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, KalVista Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
KalVista Pharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, KalVista Pharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
KALV is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
KalVista’s catalysts are sebetralstat and the hereditary-angioedema program, where regulatory and commercialization steps matter most. The stock will react if the program keeps moving cleanly toward launch.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
Source: KalVista Pharmaceuticals, Inc.
- 02
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
Source: KalVista Pharmaceuticals, Inc.
- 03
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
Source: KalVista Pharmaceuticals, Inc.
- 04
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
Source: KalVista Pharmaceuticals, Inc.
- 05
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
Source: KalVista Pharmaceuticals, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.